Biomind Labs Inc.
BMND
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -12.98% | 4.24% | 46.33% | 13.12% | -46.48% |
| Depreciation & Amortization | -- | 0.00% | -- | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.75% | 4.07% | 2.16% | -29.32% | -69.82% |
| Operating Income | 14.75% | -4.07% | -2.16% | 29.32% | 69.82% |
| Income Before Tax | 45.07% | 64.12% | 163.32% | 72.53% | 41.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 45.07% | 64.12% | 163.32% | 72.53% | 41.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 45.07% | 64.12% | 163.32% | 72.53% | 41.26% |
| EBIT | 14.75% | -4.07% | -2.16% | 29.32% | 69.82% |
| EBITDA | 12.98% | -4.24% | -1.65% | 24.85% | 70.24% |
| EPS Basic | 46.43% | 64.00% | 161.11% | 76.47% | 41.67% |
| Normalized Basic EPS | 50.00% | 31.25% | 160.87% | 72.73% | 40.00% |
| EPS Diluted | 46.43% | 64.00% | 161.11% | 76.47% | 41.67% |
| Normalized Diluted EPS | 50.00% | 31.25% | 160.87% | 72.73% | 40.00% |
| Average Basic Shares Outstanding | 3.76% | 3.76% | 3.76% | 3.62% | 0.00% |
| Average Diluted Shares Outstanding | 3.76% | 3.76% | 3.76% | 3.62% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |